Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy”.
-
Clinical Benefit
Substantial
The actual benefit of PLAVIX in this new indication is substantial.
Clinical Added Value
moderate
The Transparency Committee considers that in this new indication, PLAVIX provides a moderate improvement in actual benefit (IAB III) for patient management.
Listen
